Podcasts about responses

Our guest this week is Houston Curtis. Houston is a sleight of hand expert, and executive producer of the live streaming poker show "Live At The Bike." We talk about some of the recent poker cheating scandals and what you can do to protect yourself. He is also the author of Billion Dollar Hollywood Heist, and his experiences playing in "Molly's Game."We welcome your questions - send them to us at gamblingwithanedge@gmail.com, or you can find me at @RWM21 on Twitter or https://www.facebook.com/GamblingWithAnEdge.Show Notes[00:00] Introduction of Houston Curtis, sleight of hand and game protection expert[00:41] GWAE is changing podcast platforms[02:23] Live at The Bike[07:45] Limon[08:46] Cheating in card games[13:28] RFID, hole cards, Mike Postel, home games[20:09] Shufflemaster vulnerabilities in Texas[27:47] South Point Casino July Promotions - $25k and $1k-$2.5k casino wide progressives[28:33] http://BlackjackApprenticeship.com - blackjack training site with analytical software, training guides, members forum, and chat room[29:04] http://VideoPoker.com/gwae - Gold Membership offers correction on most games, free Pro Membership trial for GWAE listeners [30:40] Houston's video content[34:24] Using cheating knowledge to protect games versus to cheat games[35:34] Responses to cheating and proactive measures like limiting dirty money, social media[39:18] Selecting players for Live at the Bike[43:59] Producing 1,000 hours of content per year[44:58] Houston's upcoming book, Million Dollar Mechanics, to be published by The Huntington Press[47:13] Steve Forte[52:09] Recommended - The Old Man on FX and Hulu, How to Tell a Story audiobook by The Moth, Live at The BikeSponsored Links:http://SouthPointCasino.comhttp://BlackjackApprenticeship.comhttp://VideoPoker.com/gwaeGuest Links:http://Twitter.com/houston_curtishttp://Kardsharp.comhttp://Liveatthebike.comBillion Dollar Hollywood Heist https://amzn.to/3AlyhT4Recommended:http://Fxnetworks.com/shows/the-old-manHow to Tell a Story by The Moth https://amzn.to/3xVGBX2http://Liveatthebike.com

Lindsey Myers, ASTHO's Vice President for Social and Behavioral Health, discusses a new blog article she authored with Chief Medical Officer Dr. Marcus Plescia about men and gun violence; Dr. Steven Stack, Commissioner of the Kentucky Department for Public Health, details the latest information about a rash of hepatitis cases among children; and public health officials in Maine want young people in their state to know how much they matter. ASTHO Blog Article: Men and Firearms: Proven Public Health Interventions to Curb Violence Kaiser Permanente Webpage: Leadership and innovation to prevent gun injuries and deaths WVXU News Article: Kentucky and Indiana investigating potential hepatitis cases in children Public Health Review Podcast: Making Sure Maine Youth Matter

This weeks lineup:Warmup Segment:Listener Question: How quickly should a player be able the change a bad habit? (@12:11)Paige's Power Play (@18:23)We had some good responses to our topic on loyalty. There are some more things to consider. (@24:03)How do we make the pro-leagues work? (@36:54)We have to teach sliding better. Let's eliminate the collisions. (@50:55)Support the show

Got some great responses on today's D-bag.

In a landmark opinion issued June 24, the U.S. Supreme Court has overturned Roe v. Wade, 410 U.S. 113 (1973), and Planned Parenthood v. Casey, 505 U.S. 833 (1992). Responses across the country have been mixed — from celebration by pro-life organizations to outrage and protests from pro-abortion groups. But what does the opinion mean for Texas? “The Supreme Court does not make law, nor does it create new individual rights,” said retired U.S. Army Lt. Col. Allen West, a former candidate for Texas governor, who previously served as chairman of the Republican Party of Texas. The court, he said,...Article Link

O.J. Simpson has weighed-in on The Supreme Court overturning Roe V. Wade. Legendary Voice Of 93WIBC Stan Lehr reads some of the responses to O.J.'s tweet. See omnystudio.com/listener for privacy information.

A new MP3 sermon from Salem Bible Church is now available on SermonAudio with the following details: Title: 22. Gospel Responses in Thessalonica and Berea Subtitle: Paul's Missionary Journeys Speaker: Jim Delany Broadcaster: Salem Bible Church Event: Sunday - AM Date: 6/26/2022 Bible: Acts 17:4-14 Length: 55 min.

Today we will be studying in the book of Matthew (SUNDAY 06/26/22) Today's sermon will be looking at Matthew 13:18-23 "Man's Differing responses to the Word: Prep for Nehemiah 8"

Guest Host: Tim Barnett   Tim and Alan continue their discussion about responses to popular pro-choice memes that say the Bible gives instructions on how to perform an abortion, if you don't support requiring vasectomies for men, you shouldn't support controlling women's bodies, and nobody has the right to use your body against your will.   Topics: More responses to popular pro-choice memes. (00:00) The only time the Bible mentions abortion is to give you a magic potion to perform one. (02:00) If you don't support giving every young man a reversible vasectomy, then don't support controlling women's bodies. (12:00) It doesn't matter when life begins because nobody has the right to use your body against your will. (17:00) Mentioned on the Show:  Did God Ordain Abortion as Punishment for Infidelity? by Alan Shlemon Related Links: Pro-Life Crash Course by Amy Hall Only One Question (What Is the Unborn?) by Greg Koukl Does This Bible Verse Support Abortion? by Tim Barnett (Red Pen Logic) Do Pro-Lifers Want the Government to Regulate a Woman's Body? by Alan Shlemon Unstringing the Violinist by Greg Koukl A New Response to the Violinist Argument by Amy Hall

If the world has become too much to bear—and the bots know it from your search history— you will likely find Teal Swan. She will appear, an angel of the algorithms, part icon and part anime avenger. Against a backdrop of flowing water or turning constellations, she will gaze into your despair. She will speak in a drone at once hypnotic and relieving, giving words to feelings you thought were taboo. At 3am, this might feel like mystical luck, but it's no accident. Swan is open about recruiting suicidal seekers to her content, and she has the tech chops to do it.Now, with Jon Kasbe's series, “The Deep End” airing on Hulu, Swan has entered some A-list limelight. But what do we really learn from this docutainment event, radiating out from an embedment in Swan's inner circle? According to Kasbe's own words, we don't learn the “Capital T Truth” of Swan's day-to-day, but rather the immersive feeling of what it is like to be under her spell. Or do we? Swan accuses Kasbe of casting his own spell, with deceptive editing that scrambles timelines and conflates interactions, and even different people. And it appears she might not be wrong. We talk to Kasbe in this episode about his vision and blindspots, and the ironic risk of creating a film of Satanic-Panic level false memories about an influencer who says she specializes in retrieving past trauma. This episode will pilot a series of Patreon bonus episodes in which we'll study the Teal Swan spectacle in detail, and how important it is to not only report on it well, but to be fair to an influencer like Swan and her dedicated followers, lest they lose even more trust in the real  world.Show NotesThe Deep EndThe Gateway Podcast Teal Swan 2014 interview on her backstory.Teal Swan: Gucci Guru article by Be ScofieldBarbara Snow's seminal Satanic Panic article: Ritualistic Child Abuse In A Neighborhood SettingRecovered Memory Therapist Placed on ProbationMichelle Remembers & The Satanic PanicTeal's Responses to The Deep End Start HERETeal Swan Defense :Testimonial Deep End Defamation—Sylvana Caradonna 

Dr. Diwakar Davar and Dr. Jason Luke, both of the University of Pittsburgh's Hillman Cancer Center, highlight key advances in early phase therapeutics and immunotherapy that were featured at the 2022 ASCO Annual Meeting and also address toxicities, including immune checkpoint inhibitor-associated myocarditis. TRANSCRIPT Dr. Diwakar Davar: Hello, and welcome to the ASCO Daily News Podcast. My name is Dr. Diwakar Davar, and I'm an assistant professor of Medical Oncology, specializing in melanoma and phase 1 therapeutics at the University of Pittsburgh's Hillman Cancer Center. I am the guest host of today's podcast. My guest today is Dr. Jason Luke, a colleague and the director of the Cancer Immunotherapeutics Center at the UPMC Hillman Cancer Center here.  Today, we'll be discussing advances in early-phase therapeutics and immunotherapy that were featured at the 2022 ASCO Annual Meeting.   You'll find our full disclosures in the show notes, and the disclosures of all guests on the podcast are available on our transcripts at asco.org/podcasts.  Jason, thank you for coming on the podcast today.  Dr. Jason Luke: Thanks so much for the invitation. It was a great ASCO, and I hope everyone had a good time.  Dr. Diwakar Davar: So, onto our abstracts. So, the first one that we'll be discussing, and Jason as you know we've done this before. We'll be rapidly transitioning between phase 1 therapeutics, melanoma, and advanced phase 2 and 3 trials, but you know this is something you do very well. So Abstract 2504, it's a phase 1 trial of TIM-3 inhibitor cobomilab immunotherapy and in combination with PD-1 inhibitors nivolumab and dostarlimab. The AMBER Trial that was presented recently, and in full disclosure, both you and I actually are on this abstract. So, what do you think of this abstract? What do you think of the data that is discussed, and how do we contextualize this in relation to what needs to be done in this space?  Dr. Jason Luke: So, I think this is an exciting abstract because it brings forward what may be the next high-priority immune checkpoint to try to target in clinical oncology. To level-set, I think everybody listening will know about PD-1 and CTLA-4 as immune checkpoints. In the last year, we've had LAG-3 come forward as now a standard of care element of armamentarium in melanoma, and we look forward to further studies of LAG-3 and other tumor types as we think it should be a good partner where PD-1 is otherwise approved.  So here now, we hear about TIM-3, which is another negative regulatory checkpoint on a number of different immune subsets. And in this abstract, the antibody targeting TIM-3 was cobolimab. So, TIM-3 is a very interesting molecule. It has, what you might call, pleiotropic effects in the immune system. So, while in the context of this abstract, it was being targeted as another immune checkpoint on T cells, it's important to point out that TIM-3 has other regulatory roles in other immune subsets such as myeloid cells and very particularly dendritic cells, and that's important because it might bring in another element of the innate immune system to try to drive anti-tumor responses. So, it's an exciting target because it might be able to expand the groups of patients who could benefit from immune checkpoint blockade.  So, in this abstract, we see initially the phase 1 data of combining cobolimab, anti-TIM-3 with anti-PD-1 of a couple of different flavors. And what you could take from this abstract is that in the phase 1 setting, the drug was well-tolerated and combined well, and had pharmacokinetic properties that would be consistent with what we'd expect for this kind of a monoclonal antibody. I think we have to marry this abstract, which is really the phase 1 data about safety in pharmacokinetic (PK) to another abstract presented in the melanoma session, which showed an expansion cohort of patients who got cobolimab plus nivolumab or dostarlimab.  And there we did see a 50% response rate, albeit that there was heterogeneity of patients being treatment naïve versus treatment-experienced. So, what I would say to this on a high level is that I think these data are preliminarily exciting, suggesting that further investigation into TIM-3 may be valuable in terms of expanding the population of patients initially in melanoma, but there will data coming soon in lung cancer and in other tumor types with another novel checkpoint. And I think if we think ahead into the future, the question is probably going to end up being, which combinations of checkpoints for which patients. That's pretty exciting to think about. We've seen a lot of data of PD-1 plus other molecules, and I think some future biomarker stratification really will be necessary to know which patient would benefit the most from which of these combos, but for the time being, this is exciting data to see where the field is going to go over the next couple of years.  Dr. Diwakar Davar: Great. And I guess, to your point, one important thing to highlight from the abstract is your point about the role of the different compartments. There was actually a very interesting dose-response relationship with the highest dose of the drug not necessarily being the most effective dose, suggesting that yes, as you escalate, you may have different effects in different compartments, and maybe therefore a broad selection of doses might be required to ensure that you have optimal engagement of the optimal target.  So, the next abstract is Abstract 3007. This is the tumor-agnostic efficacy and safety of erdafitinib. So, we now know that FGFR pathway aberrations are found from 77% of all malignancies, FGFR targets are now U.S. Food and Drug Administration (FDA) approved in cholangiocarcinoma with pemigatinib, infigratinib, and as well with erdafitinib metastatic urothelial cancer. We know that these agents are not necessarily effective tests in 1 tumor type because these alterations have risen in multiple tumor types. So, the RAGNAR trial, looking at this across multiple tumor types, what do you make of the interim analysis result presented by Dr. Loriot?  Dr. Jason Luke: So, I'd say that this is probably the future of targeted therapy. And so, I think that where we have activity in 1 disease, it's very likely we would have activity in others. So, the author has described this as the largest basket trial of a molecularly defined subset that's been pursued to date. There are upwards of more than 200 patients in the study. I think it's really important, as we think about the data, to realize, though, that all FGFR alterations are not exactly the same thing. And so, in this study, they gave erdafitinib to patients with solid tumors of any FGFR altered status. And so that's FGFR1, 2, 3, 4 mutations or gene fusions. And that's a lot of heterogeneity in there actually.  And in this study, there were two-thirds fusions and one-third mutations, mostly in FGFR2 and 3. That will become relevant as we start to think about the results. On a high level, I have to say that it is impressive in pan-cancer fashion, just selecting by FGFR alteration, there's about a 30% response rate observed. I think that no matter what, that's going to be valuable considering these were patients with refractory tumors with 3 lines of prior therapy on median. I think what we need to know more is the breakdown of which specific molecular alteration and FGFR in which tumor types drove most of the benefit.  So, for example, in bladder cancer where erdafitinib is already approved, that's almost entirely an FGFR3 fusion setting. So we know the drug is effective there. And so I think there will be a further breakdown of the data. As it matures more, you really start to tease out, is it really the case that any FGFR alteration can be treated or there are some that really ought to be the high priorities that we really ought to be going after. I think it would be remiss not to also note, however, that while there's excitement about this sort of pan-cancer approach, the current generation of FGFR inhibitors are not exactly the easiest drugs to take.  And so, the in-class, hypophosphatemia and stomatitis really does lead to dose reductions in a lot of the patients. And I think that that's probably really important to emphasize is that despite the pan-tumor activity, there's still a lot of potential in this field to refine further because it's almost certainly the case that if we had less off-target toxicity, so to say, we could improve the efficacy beyond that 30% that we saw here.  All the same, I think this is exciting for the concept of a pan-cancer tumor agnostic sort of approach, and we'll really look forward to more data to come from this study over the next, hopefully, few months.  Dr. Diwakar Davar: And I guess 1 corollary to that is that we now need to start looking for FGFR alterations in multiple tumor types. So, tests, tests, tests. All right, Abstract 3004, phase 1a/1b dose escalation and expansion study of the MDM2-p53 antagonist BI 907828 in patients with multiple solid tumors including advanced, metastatic, liposarcoma. So, we've recently had data of the previously undruggable KRAS, and now we've got previously undruggable p53, for which we now have targets. So, Jason, what do you make of the p53 targeting approach, in this case, using MDM2 and this particular drug from Boehringer Ingelheim?  Dr. Jason Luke: So, I think that this is an exciting abstract exactly for the reason that you mentioned, which is that p53 has been, and unfortunately, to some degree, still remains, one of those holy grails but undruggable targets in oncology. So MDM2, for those who are listening but might not be aware, is a negative regulator of p53. So, the concept here then is if you drug it, you might release p53 to reactivate activity in that pathway, and then p53 being the guardian of the genome, so to say, potentially leading to apoptosis of cancer cells.  And so, this drug binds MDM2 and MDM2 can be amplified as a resistance mechanism in p53 and several tumor types. And so here, they showed data for the early part of a clinical trial investigating the small molecule, BI 907828, but then they focus specifically in liposarcoma, which is a disease known to be an MDM2 amplified. And so, the results were pretty interesting. The toxicity of this kind of an approach, just to note, is really in class. It leads to some gastrointestinal (GI) toxicities as well as hematologic problems, and this goes again for most regulators of the cell cycle will have these effects, whether they're CDK inhibitors or MDM2 or p53 modulators.  But I think what was very interesting, this is a disease liposarcoma where chemotherapy, functionally speaking, has no role. We, unfortunately, give it to some patients sometimes, but it has almost no activity, and they observe that in poorly differentiated liposarcomas, the response rate was about 12%, but the stable disease was quite durable. And so, I think that really is potentially a big deal because this is an orphan disease. It really lacks any other treatment. But as you zoom out from that, if you start to think about targeting amplified MDM2 in other settings, I think the activity that we see here is intriguing, and potentially suggests that we may be coming to a future where we'll have multiple, sort of, orthogonal approaches after reactivating p53. There were actually other abstracts at ASCO Annual Meeting of other molecules that were less mature also along this line.  So, I think, very exciting to take away from this, one, a potential treatment for liposarcoma for all of those patients that anybody listening actually sees, but secondarily this concept of targeting p53, which I think we'll see a lot more of over the next couple of years.  Dr. Diwakar Davar: Excellent. Moving on to the Abstract 3002, this is a phase 1, two-part multicenter, first-in-human study of DS-6000a of an antibody-drug conjugate comprising the anti-CDH6 IgG1 monoclonal antibody that is attached to a topoisomerase I inhibitor payload via a cleavable linker. And so basically, a way in which you can give topoisomerase: (1) TOP1 inhibitor, (2) CDH6-expressing cells. This was studied in advanced renal cell carcinoma (RCC) and advanced ovarian cancer in this abstract presented by Dr. Hamilton. Jason, what do you think of the results and what do you think of this approach in general, this antibody-drug conjugate (ADC) approach using novel targets as well as novel payloads?  Dr. Jason Luke: I think this is one of those that you can't help but be pretty excited about, and I think in the context of the data shown at the plenary session in breast cancer for antibody-drug conjugates (LBA3), I think this is really where the field is going to start to go. So, you mentioned that this is an antibody-drug conjugate that targets cadherin 6 or CDH6, which people will remember from biochemistry class and medical school, or something is a cell-cell adhesion molecule, really a basement membrane protein. So, the concept of targeting it really is just to go after a latch mechanism to get the molecule into the tumor where you want. And CDH expression is very high in renal cell carcinoma, upwards of 80% of samples, also high in ovarian cancer, which is why they chose those 2 tumors to go after.  So, the ADCC, and you described its structure just a little bit, but it's essentially the same backbone as trastuzumab deruxtecan, which we saw this outstanding activity for HER2 and breast cancer on the plenary, with these 8 chemotherapies moieties attached to it, but here now, targeting it instead to HER2, with this molecule now to CDH6. And I think, again, you can't help but be impressed. There were treatment responses on almost every dose level of the dose escalation in this study. There's in fact only 1 patient whose tumor was not, at least, stable disease or a PR, and I think that that just goes to show the power of truly bringing the chemotherapy in a targeted manner into the tumor microenvironment. Responses were heterogeneous. They were not super deep responses per se, but the stable disease was quite durable in the study, and the patients were going out more than 7 months. And again, realizing this is at the lower dose levels as we're increasing the dose and move this in their earlier lives of therapy is likely to be even more effective.  They did show a waterfall plot of the reduction in CA 125 for the patients with ovarian cancer that really looked quite impressive. And given that that's our clinical biomarker that we commonly follow, it may actually even more indicative of the benefit we would see as opposed to resist.  Now, again, there is some toxicity. It is a chemotherapy moiety that's conjugated to the ADCs. So, the most common toxicities were nausea, vomiting, and low platelet counts, but these are kind of toxicities that we're quite accustomed to with chemotherapy. Just to summarize, I think there's a lot of promise for this kind of antibody-drug conjugate targeting, and I think it can only be impressive that they had this amount of activity in the dose escalation of the study. [I] very much look forward to the expansion cohorts in renal and ovarian, which we'll presumably expect to see later this year, early in the next year.  Dr. Diwakar Davar: And as you alluded to, this really was parallel that ASCO, by the standing ovation given to Dr. Modi when she presented the DESTINY04 data of trastuzumab deruxtecan in HER2-low breast cancer, basically now redefining breast cancer from 4 camps, now we have to think of not just HER2 amplified or HER2-high, but also HER2-low. So yes, really have to now rethink how we classify these diseases (LBA3).  So Abstract 2509, the efficacy of anti-PD-1/PD-L1 immunotherapy in non–small cell lung cancer dependent based on CD8 and PD-L1 status. So really Dr. Galon taking us into what he has now described as the immunoscore—really a way of characterizing tumors. A way of thinking about tumors that you've also championed, Jason, in terms of this T cell-inflamed and uninflamed hypothesis. So, tell us a little bit about how these jives with your work and how you would think about lung cancer patients responding and not responding to immune checkpoint inhibitors (ICI) therapy in this context?  Dr. Jason Luke: Yeah. I think the focus quickly here on the immunoscore, so the people are aware of that, I think is really important for diving into these specific results. You have to realize our fundamental underlying predicate for immune checkpoint blockade inhibitor response is that patients have mounted an adaptive immune response. So, CD8 T-cells have gone into the tumor where they elaborate chemokines and cytokines like interferon gamma, which upregulates the expression of PD-L1 in the tumor but also in the surrounding immune cells.  So, you realize that even though antibodies are targeting PD-1, it's really that we're targeting that tumor microenvironment. So, the more robustly we can measure that, and we understand it, the more likely we are to know whether or not the patient is going to benefit. So, this is where the immunoscore comes in. The immunoscore is actually a fairly simple test. It's one slide, immunohistochemistry slide where they can stain jointly for CD8 and PD-L1 on the same slide. And that allows them to do a number of different things beyond just testing the total level of PD-L1. They can test the CD8 density, the PD-L1 expression, but then also the interaction between CD8 T-cells, their distance from each other, from PD-L1 expressing cells, and so on and so forth.  And so really [this] can give us a much more robust analysis of what all is going on in the tumor microenvironment again, off of a single slide. So here then, in this abstract, for patients with non–small cell lung cancer receiving anti-PD-1, they then compared the utility of only PD-L1 testing versus doing the immunoscore. And so, it was actually quite a large set. They had about 250 patients in their analytical set and then split about 150 or 180 or something into the training and validation sets, and they compared the immunoscore against 2 different standard PD-L1 antibodies, the 22C3 as well as the SP263. And what they saw was a high concordance for expression between PD-L1 and the immunoscore.  That's good, because, again, they're measuring PD-L1 in both of those. And so that was a good, sort of, level set. The immunoscore, however, allows them to look to 7 different parameters, again, beyond just PD-L1, as I mentioned. So, CD8 density, interaction, distance, and this kind of thing. Then in these test and training cohorts, they were able to actually split out patients who are PD-L1 positive into further groups, those that were immunoscore low and that were high. And in so doing, they were actually able to sort of dramatically predict the likely progression-free survival on PD-1 checkpoint blockade in those different non–small cell lung cancer groups.  So why is this important? Selection of patients by PD-1 has been very useful in the field of non–small cell lung cancer, but it's hardly a panacea. You're not at all assured your patient is going to do well just because they're PD-L1. And here comes a second assay that can be done in a standard of care setting. So, the immunoscore is a test. You could just order it, and that really does give you much more predictive power about who's likely to do well and who isn't. And I think this test and more broadly multi-spectral imaging is really going to become a core component to how we risk stratify and predict outcomes to checkpoint blockade and lung cancer, but broadly in other tumor types over the next couple of years.  Dr. Diwakar Davar: Okay. Now, moving on from a biomarker for PD-L1 and PD-1 to a setting in which PD-1 was just recently U.S. Food and Drug Administration (FDA)-approved, so I'll give a brief background to the trial that you've actually developed and led. And so, this is KEYNOTE-716, the abstract in question is LBA9500 (late-breaking abstract) 9500, but this is the distant metastasis-free survival (DMFS) data readout. The DMFS, distant metastasis-free survival with pembrolizumab versus placebo in the adjuvant setting for patients with stage IIB or IIC, that is high-risk node-negative melanoma and the data from the phase 3 KEYNOTE-716 study.  So, this data, at least the recurrence-free survival (RFS) data was actually earlier published, you had presented it earlier last year and also more recently this year, but it was published recently in Lancet. And we know that 716 is a study in which, for the first time ever, we have an immune checkpoint inhibitor PD-1 that was studied against placebo with the high-risk node-negative setting in stage IIB and C melanoma, demonstrated a significant RFS benefit in the setting against placebo. And now we have the DMFS readout.  Maybe you could tell us a little bit about both the RFS and the DMFS data, and why this is such an important advance for these patients.  Dr. Jason Luke: Thanks. And I agree this really is a sea change in how we thought about stratification of patients with melanoma, but I think this broadly has implications for other tumor types as well. So, in melanoma, we've historically thought of its involvement of the lymph nodes—stage III as being the high-risk disease, but we also, if you look at the outcomes from the AJCC, we see the patients with stage IIB and IIC, so deep primary lesions, actually have similar bad outcomes as those patients with stage IIIA and IIIB. And so anti-PD1 and adjuvant therapy and melanoma were originally proved for stage III, but having understood that about 5 years ago actually, started to think, well, why not also treat the patients with stage II if they're at similar risk.  And we pursued KEYNOTE-716 as you mentioned, and it read out last year as a positive trial for recurrence-free survival. And the abstract here then was to look at the impact on distant metastasis-free survival. So, while the regulatory consideration for approval, and it is approved and it's available for patients now, was based on relapse, what we really want to be preventing is the development of metastatic disease because presumably that would correlate with the eventual death of the patient from cancer.  So, in the abstract here, we see the first update for DMFS, which also was positive on its first analysis, the hazard ratio at 0.64. And so, again, very similar to the RFS benefit, showing about a 35-36% reduction in distant metastasis-free survival. And this is a theme that we've seen across adjuvant studies in melanoma, all the adjuvant studies in fact, is that the RFS improvement, the relapse-free survival hazard ratio mirrors very closely the distant metastasis-free survival ratio. We saw that again here. I think it just emphasizes that anti-PD-1 immunotherapy is highly effective in melanoma no matter what stage it's in, but rather related to the risk of death for melanoma.  And so this really has a practice changing in the field of melanoma oncology. Patients need to be referred to medical oncology early for discussion around risk stratification and consideration of adjuvant therapy—I think even at the same time that they're having resection of their primary lesion, and it even calls into  question of whether or not we should even fully be doing procedures like sentinel lymph node biopsies any longer, considering we can make the decision to give adjuvant therapy now based on the primary—albeit that's a controversial area of discussion.  And I would just love for this to start to penetrate into other disease settings. We've seen more recently, approval for neoadjuvant therapy in lung cancer and we see in kidney cancer, bladder cancer. We see adjuvant therapy in—I think we're going to see immunotherapy starting to become an important part of the armamentarium in these hard-to-treat cancers, even at the time that perioperatively before or after surgery.  So definitely a major change in the way we're thinking about stratifying patients and emphasizes that you need to get those patients with melanoma in to have that discussion around adjuvant therapy probably at the time of the primary lesion resection.  Dr. Diwakar Davar: And finally, Abstract 2507, single-cell profiling of human heart and blood in patients with checkpoint inhibitor-associated myocarditis. So, this is data from the NGH Group, Dr. Villani and colleagues are presented by Dr. Blum. We know that myocarditis is an uncommon but very serious immune related adverse event (irAE), and here in this particular dataset, this group which has done a lot of underlying work to really uncover the role of certain key phenotypes, cellular phenotypes, in the development of myocarditis it's presenting the data in the context of ICI-related myocarditis. So, what do you think of this data, what do you think of the use of checkpoint inhibitors are now, as you've said, migrated linear in the lifecycle of the patient, what do we need to be thinking about and how does this improve our understanding of both the use of the drug and what we need to be worried about?  Dr. Jason Luke: I think the toxicities of immunotherapy, while, less frequent than, say, chemotherapy, can actually be more disastrous. In the rare patients, we have extreme immune-related adverse events, there is an incidence of actually life-threatening and fatal events. And so, myocarditis, associated with checkpoint blockade, is one of those things that could be seen, and here at ASCO Annual Meeting, we saw a couple of abstracts summarizing the experience from the National Cancer Institute following myocarditis events, and then this abstract in a translational level trying to better understand what is actually going on in terms of the immune response in those myocarditis cases.  And so, I thought this was actually a very interesting abstract. There was only a small number of patients. They had 13 samples from patients who had had endomyocardial biopsies in the context of immune-related myocarditis, and you might say, well, only 13 samples, but fortunately, this is quite a rare event, less than 1% of patients who get immune checkpoint inhibitors. And what they saw was relatively unsurprising, which is that in patients who were having myocarditis, they saw an increase in T cells and in K-cells, as well as activated CD8 and CD4 T-cells.  I think what was very interesting was when they started to dig into what were the phenotypes of the cells and what were the pathways that were turned on. Again, it was not especially surprising to see that they saw increased levels of interferon signaling and immune-receptor signaling as well as motility and adhesion, but this really, I think emphasizes that there are potentially interventions beyond just the general immune-suppression approaches that we give. They could be more nuanced but perhaps more efficacious because sadly, patients do pass away when they develop this. And in their cohort of 13 patients, 3 of those patients died. And specifically, in looking in those 3 patients, they actually saw that all 3 patients had a shared T cell cluster. And they can't exactly say what it is exactly yet, but I think it's very interesting to see that because it suggests that there's probably something about the T cell response in those patients that disproportionately triggered a fatal event.  And if we can understand that better, we then may be able to really tailor our interventions in a way that is more useful. Because, frankly, the way these patients usually present is they show up in the emergency room (ER), and they're seen by an ER doctor who thinks they're having acute coronary. They ship them off to the catheterization (cath) lab. They open him up, and then they get in there, and there's nothing going on. There's no plaque. And so now, all of a sudden, everyone is quite confused. And so, if we had better ways to search for that ahead of time to be aware of it, we might have better interventions because usually what happens right at that moment is everybody gets very confused and starts calling the oncologist, and we start slapping on steroids and other immunomodulatory agents, but sometimes it's late.  So, I think this is a great abstract. It's really starting to preliminary give us an idea of what is the actual biology that underpins these terrible events, and we can hope that we can build off that over time hopefully to eventually come up with better predictors and then obviously better interventions to try to avoid these outcomes in a small but real number of patients.  Dr. Diwakar Davar: Excellent. One other point is you and I are both involved in drug development, and as we start thinking of side effects. Side effects are really on the flip side of responses in drug development. So really 1 point to make of this is that when people start developing side effects rather than, as you say, putting your hands up in the air and waving them around, 1 of the things that we should be doing in drug development is possibly biopsying these patients because we could get new PD insights into how these drugs work, why they work, and particularly which sub-populations themselves they work on, particularly in the early-drug development setting when you oftentimes don't have that many responses.  With that, thank you, Jason, for sharing your insights with us today.  Dr. Jason Luke: Thank you.  Dr. Diwakar Davar: And thank you to our listeners for your time today. If you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. So, thank you for your attention, and we will sign out.      Disclosures:  Dr. Diwakar Davar:   Honoraria: Merck, Tesaro, Array BioPharma, Immunocore, Instil Bio, Vedanta Biosciences  Consulting or Advisory Role: Instil Bio, Vedanta Biosciences  Consulting or Advisory Role (Immediate family member): Shionogi  Research Funding: Merck, Checkmate Pharmaceuticals, CellSight Technologies, GSK, Merck, Arvus Biosciences, Arcus Biosciences  Research Funding (Inst.): Zucero Therapeutics  Patents, Royalties, Other Intellectual Property: Application No.: 63/124,231 Title: COMPOSITIONS AND METHODS FOR TREATING CANCER Applicant: University of Pittsburgh–Of the Commonwealth System of Higher Education Inventors: Diwakar Davar Filing Date: December 11, 2020 Country: United States MCC Reference: 10504-059PV1 Your Reference: 05545; and Application No.: 63/208,719 Enteric Microbiotype Signatures of Immune-related Adverse Events and Response in Relation to Anti-PD-1 Immunotherapy  Dr. Jason Luke:   Stock and Other Ownership Interests: Actym Therapeutics, Mavu Pharmaceutical , Pyxis, Alphamab Oncology, Tempest Therapeutics, Kanaph Therapeutics, Onc.AI, Arch Oncology, Stipe, NeoTX  Consulting or Advisory Role: Bristol-Myers Squibb, Merck, EMD Serono, Novartis, 7 Hills Pharma, Janssen, Reflexion Medical, Tempest Therapeutics, Alphamab Oncology, Spring Bank, Abbvie, Astellas Pharma, Bayer, Incyte, Mersana, Partner Therapeutics, Synlogic, Eisai, Werewolf, Ribon Therapeutics, Checkmate Pharmaceuticals, CStone Pharmaceuticals, Nektar, Regeneron, Rubius, Tesaro, Xilio, Xencor, Alnylam, Crown Bioscience, Flame Biosciences, Genentech, Kadmon, KSQ Therapeutics, Immunocore, Inzen, Pfizer, Silicon Therapeutics, TRex Bio, Bright Peak, Onc.AI, STipe, Codiak Biosciences, Day One Therapeutics, Endeavor, Gilead Sciences, Hotspot Therapeutics, SERVIER, STINGthera, Synthekine  Research Funding (Inst.): Merck , Bristol-Myers Squibb, Incyte, Corvus Pharmaceuticals, Abbvie, Macrogenics, Xencor, Array BioPharma, Agios, Astellas Pharma , EMD Serono, Immatics, Kadmon, Moderna Therapeutics, Nektar, Spring bank, Trishula, KAHR Medical, Fstar, Genmab, Ikena Oncology, Numab, Replimmune, Rubius Therapeutics, Synlogic, Takeda, Tizona Therapeutics, Inc., BioNTech AG, Scholar Rock, Next Cure  Patents, Royalties, Other Intellectual Property: Serial #15/612,657 (Cancer Immunotherapy), and Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)  Travel, Accommodations, Expenses: Bristol-Myers Squibb, Array BioPharma, EMD Serono, Janssen, Merck, Novartis, Reflexion Medical, Mersana, Pyxis, Xilio  Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.     

Man did we get some responses on todays d-bag.

Our interview with Bill Montevecchi on the cormorant control measures earlier this week ruffled a few feathers. We bring you responses from the provincial government and the provincial aquaculture industry.

I Cor 10 - Develop your Responses. www.myntcc.org/jacksonvillefl

Breaking News, Trending News, Making Headlines, Latest News, weather, top local stories, international stories, celebrity news and Russian Invasion Of Ukraine. Send your videos and pictures to media@mdntv.live. Rich, online digital channel bouquet to pick from [www.mdntv.live]. No dull moments here, Monday to Sunday, 24/7. We stoop to satiate your online desire. There is something to entertain, inform, educate, enrich you, your family, and all. Watch directly and LIVE STREAM on https://www.mdntv.live LISTEN ON MDNTV THE PODCAST ️Available on all digital platforms https://link.chtbl.com/3O9k3mdF For Interviews and news email interviews@mdntv.live For Advertising advertising@mdntv.live #Mdntv #MdnNews #thisismedia #media #whatthemediawillnotshowyou #whatthemediawontshow #medias #mediaperson #me #press #reporters #tvhost #tvhostnews #freshnews #tv #television #news #meme #viral #india #new #bhfyp #indonesia #usa #trending #sport #hiphop #video #youtube #business #football #world #sports #news #coronavirus #corona #facts #headlines #todaysnews #newsreporter #updatenews #newstoday #newsoftheday #newsupdate #latestnews #dailynews #sports #nflnews #patrickmahomes #fantasysports #nflnow #trending #nfldraft #espnnews #nflupdates #breakingnews --- Send in a voice message: https://anchor.fm/major-daughter/message

Have you ever found yourself spending more time scrolling on social media than creating content for your business, and then falling down the rabbit hole of the comparison game? Do you overanalyze your content repeatedly and feel like it's never good enough? Do you have a hard time setting up boundaries with your clients? If any of the mentioned behaviors speak to you (or maybe all of them), you might be in a trauma response and not even realize it.    That's why, in this podcast episode, I dive into different trauma responses. I break down the three most common trauma responses, how they might show up in your business, and how they influence the growth of your business. Plus, I teach you tools that will help you to combat them. Lista? Let's tune in!    In this episode, I chat about: Three common trauma responses among new and seasoned entrepreneurs Examples of behavior in your business that can help you to identify different trauma responses How to step out of the three common trauma responses and calm your nervous system   Resources from this episode: Come say hi on Instagram @lifewithhliz Join the waitlist for my signature program Aligned Coaching  Apply for 1:1: private coaching Enter the giveaway by taking a screenshot of your favorite podcast episode so far with any takeaways that you took away from the episode, post it on your Instagram stories and tag me @lifewithhliz 

Techstination, your destination for gadgets and gear.   I'm Fred Fishkin.     With the beginning of another hurricane season this month…Amazon is preparing…along with partners like Save the Children…to get emergency supplies where they are needed more quickly.  Aren Koenig is with the humanitarian response...

"Diverse Responses to the Raising of Lazarus" John 11:45-57 The miracle of raising Lazarus from the dead produced diverse responses. I. The miracle awakened faith in some but not all who witnessed it. II. The miracle aroused murderous hatred among the Jewish leaders. III. The miracle elicited an unconscious prophesy of Jesus' substitutionary atonement. Rev. Ralph A. Pontier

TODAY'S TOP STORIES // The Texas Republican Party has just formally declared that homosexuality is an "abnormal lifestyle choice" and President Biden isn't the president. //  WE NEED TO TALK about New York state giving out hundreds of robots as companions for the elderly. See omnystudio.com/listener for privacy information.

In this episode we take a look at what a guitar cabinet impulse response is, how they are used, and check out some sound samples from the FREE Fuzzlord IR Sample Pack!   Download the free IR sample pack at https://fuzzlordeffects.com/ Big thanks to all of our https://www.patreon.com/fuzzlordeffects supportors: Adam Hays Adam Johnson Adam Reissman Aidan Alex Diaz Alvin Carter III Ander Goya Andrew Encinas Anthony Jamison Art Arredondo Ben Gibbins Brendan Hooper Cadaver Head Carl Tripodi Chad Fairbanks Chad Garrett Charles Parish Charlie Biedenharn Chris Godfrey Clemens Rothbauer Cody Anderson Cody Meyers Corbin Valentina Daniel ManLow Dead Garage Don Harvey Douglas James Duane Pitre Edward Eagerton Eric Kraushaar eric lister Erich B. Heider Furious Beardsley Geep077 Howl Rabbit Ian Bessette Ian R. Davis Ilias Jake Snoddy Jake VanDeWoestyne Jasmine Andrews Jason Teeter Jed Marsillo Jeff Brancato Jeff Liu Jeff Moffett Jered Johnson Jeremiah Johnson Jerred jk wentzel Joe Jon Unruh Jose Josh Motley k_stellar_666 Karl Elvis MacRae katch Kenny Davis Kevin Hess Larry McDowell LESVOSURF Malt Liquor Mike Marcus Storch Matt M Matthew Hubenka Matthias Apel Neal Dettling Neil S Nicholas Abasolo Noah Whistler Park Kingery Pedal TV Channel Penis Massacre Peter DeVault Pietro Scorsone Rev. Thörn Richard Chapplow Ryan Ames Sabato Imperiale Sam Coddington Scott Perry Shannon m Shawn Weinman Slade Swinford Steve Chavez Steven Atteberry Sunny Page Tommy O'Brien Trading Vices Trey Bowden Troy Walker Troyfazzio Uwe Halmich Veyuslavic Weston Willy Idol  

The Pew Research Center reports that the U.S. public now views inflation as the top problem facing the country, by a wide margin. It's not hard to see why. After decades of low and stable inflation, the U.S. economy is witnessing a rate of price increase unseen since the 1970s and 80s. Why is inflation so high? Who does it hurt most? And what are the prospects for it coming down? Karen Dynan of Harvard University joins EconoFact Chats to discuss some of these questions. Karen is a Professor of Practice in the Department of Economics at Harvard University. She previously served as Assistant Secretary for Economic Policy at the U.S. Department of the Treasury.

Dr. Desirée Schmuck, Assistant Professor at the Department of Mass Communication at KU Leuven, shares her research on social media influencers and their effects on users' political attitudes and behavior. We break down three of Dr. Schmuck's studies. The first focuses on how exposure to political influencer content affects young social media users' behavior, both in terms of formal electoral participation and environmental sustainability. The second examines how influencers might affect users' perceived simplification of politics, and how that perception influences users' political cynicism and interest. The third study is an experiment that seeks to understand how misinformation from lifestyle influencers could affect female social media users' attitudes toward covid and trust in public health information. Here are links to the studies we discuss in the episode: The Mobilizing Power of Influencers for Pro-Environmental Behavior Intentions and Political Participation (2022)Politics–Simply Explained? How Influencers Affect Youth's Perceived Simplification of Politics, Political Cynicism, and Political Interest (2022)Responses to Social Media Influencers' Misinformation about COVID-19: A Pre-Registered Multiple-Exposure Experiment (2022)And if you're interested in political influencers, check out our episode on political influencers in the Biden 2020 campaign.

We talk to the creator of the FBI active shooter program about how police handled the school shooting in Uvalde, Texas. Then, we talk to a political scientist about the latest public hearings from the House committee investigating the January 6 attack on the U.S. Capitol.

Genesis Women's Shelter & Support offers domestic violence services to everyone who identifies as a woman. To improve access to services for all intimate partner violence survivors in need of safety, shelter & support, Genesis The Podcast is launching a Pride Month Podcast Series focused on intimate partner violence (IPV) in LGBTQIA+ relationships.Each episode in this series is a dialogue with survivors and/or experts highlighting the needs and issues of IPV survivors in the LGBTQIA+ community as well as possible solutions for improved responses to their experiences. Our hope is that this dialogue will grow into new collaborations across communities that expand our understanding of IPV, reduce its prevalence, and provide more equitable responses and services for all survivors of IPV in LGBTQIA+ relationships. Media consultant Ron Corning joins the conversation as co-host and interviewer for the series, offering critical insights into IPV among LGBTQIA+ partners.Solutions specific to IPV in LGBTQIA+ relationships can be challenging to resource. We've gathered experts in the fields of law enforcement, clinical services, advocacy and more to evaluate what solutions exist, the effort to include all people in those solutions and improve responses to IPV for people who identify as LGBTQIA+. Ron Corning talks with Genesis CEO Jan Langbein and senior director of residential services Jordyn Lawson to understand responses within the domestic violence movement. Maria MacMullin expands on these ideas with presenters from the 2022 Conference on Crimes Against Women who offer diverse approaches to navigating IPV across LGBTQIA+ relationships. Guests include: Sarah Berlanga of The Women's Center, Kimberly Crawford of the DC Coalition Against Domestic Violence, Michael Crumrine sergeant with the Austin Texas Police Department, and Patrick Moug of the Wayne County Prosecutor's Office, Detroit.

You just never know what we will be talking about in our podcast... and that's the best part. Press play and listen to us chat about pretty much anything and start creating awareness around your emotional responses on social media. Come find us on instagram https://www.instagram.com/yourwayweightloss/?hl=en Join our summer fun https://www.yourwayoursupport.com/10weekmembership Join our email list https://www.yourwayoursupport.com/pl/2147491149

Responses to the mass shootings in Buffalo, New York, and Uvalde, Texas, have continued, and there's renewed hope for policy changes. This week, Jo Saxton joins Phil and Skye as a guest co-host to discuss a series of articles from African-American and global Christian leaders about the need to rethink both America's gun policies and the American church's gun culture. Then, BibleProject co-founders, Jon Collins and Tim Mackie, talk with Skye about how their work has shifted from just teaching what's in the Bible to teaching people how to read the Bible. Their new app and podcast series is designed to help us see the Bible as brilliant literature, and not just a depository of quick answers to life's problems. Also this week, should we be concerned that more people are having wedding ceremonies to marry themselves? Holy Post merchandise - https://www.holypost.com/shop Getting Schooled by Kaitlyn Schiess: Political Theology 101 - https://www.patreon.com/posts/67787080/ BibleProject Patreon Bonus - https://www.patreon.com/posts/67787175/ News Segment 0:00 - Intro 4:10 - Sologamy?? 13:49 - Guns in the home 20:39 - Guns and cars 26:00 - Global perspective on America's gun culture 36:12 - Gun violence and the theology of evil 44:52 - Guns and church 54:44 - Holy Post Announcements Interview with Jon Collins and Tim MackieBibleProject: bibleproject.com BibleProject App: https://bibleproject.com/app/ BibleProject Podcast: https://bibleproject.com/podcasts/the-bible-project-podcast/ 57:09 - Jon Collins and Tim Mackie interview intro 1:00:26 - BibleProject shift toward how to read the Bible 1:06:39 - Bible literacy in America 1:19:38 - Literary beauty in the Bible Articles mentioned in news segment: “Sologamy: India woman's plan to ‘marry herself' sparks debate” - https://www.bbc.com/news/world-asia-india-61671032 “Injuries and deaths due to firearms in the home”https://pubmed.ncbi.nlm.nih.gov/9715182/ “What would it mean to treat guns the way we treat cars?” (Vox) - https://www.vox.com/future-perfect/23151852/gun-violence-cars-crashes-firearms-deaths-youth “This Love of Guns: It's Way Beyond Our Understanding” by Matthew Soerens (Christianity Today) - https://www.christianitytoday.com/better-samaritan/2022/june/this-love-of-guns-its-way-beyond-our-understanding.html “What Supporters of Gun Rights Mean When They Talk About ‘Evil'” by Esau McCalley (NYT Opinion) - https://www.nytimes.com/2022/06/10/opinion/mass-shooting-evil.html “White Churches, It's Time to Go Pro-Life on Guns” by Charlie Dates (Christianity Today) - https://www.christianitytoday.com/ct/2022/june-web-only/uvalde-school-shooting-chicago-go-pro-life-gun-violence.html

Got some great feedback on today's whose the d-bag.

Exactly what the title says, deep thoughts on small ways Taiwan has changed in the past ten years, for the everyday lives of people who live here. Responses from Reddit too! I'm coming up on ten years living here, so the next few episodes will be musings and mulling all about a decade on this beautiful island. A sense of achievement, or midlife crisis? Let's see. Send us an email at deartaiwanpodcast@gmail.com!

My last podcast episode was with Stephen Hitt where we discussed his evolution of the "in-place" model. And I was really excited for the microgym world to get a hold of it. But for some reason, there are still a high number of us that refuse to learn about new ways of doing this thing of ours. And it's going to be the downfall for most of the owners, I fear. --- Send in a voice message: https://anchor.fm/wtfgymtalk/message

Dr. Marcus Plescia, ASTHO Chief Medical Officer, discusses the tragedy of gun violence in America and its connection to men's mental health; Dr. Randall Williams, Missouri's former Health Director, talks about a book he is writing about his experiences in the position; ASTHO's Juneteenth webinar examines the impact of racism on health equity on Thursday, June 16th; and the newscast celebrates its 200th episode since its launch last August. Men's Health Month Webpage: Men's Health Week ASTHO Juneteenth Webinar: Commemorating Juneteenth A Journey to Equity

In the June 2022 episode of the Southwest Climate Podcast, Mike Crimmins and Zack Guido apologize for the extended (and unintentional) break from podcasting, before diving into to a wide ranging "catch-up" episode that recaps winter and spring conditions, discusses regional hazards we see in spring into summer, and touches on the forecast and outlook for the summer...and the monsoon! They wrap with a discussion of the monsoon, whether this year could ever live up to last year and what led to last year's conditions, before addressing the excitement that a few outlooks have caused, and the early storms that have been building to the south. They also discuss the return of the Monsoon Fantasy Game and talk about how you can play and test your forecast skills against the "experts".  Happy Monsoon!  For more information on the monsoon, be sure to check out the updated Monsoon Tracker from NWS Tucson: https://www.wrh.noaa.gov/twc/monsoon/monsoon_tracker.php. Monsoon Fantasy Forecast Game The monsoon fantasy forecast game is back!  The game is largely the same. You make rainfall forecasts at five cities each month. You score points based on the accuracy and riskiness of your forecasts. Here's what is new this year: You can make your forecasts for the month until midnight the final day of the previous month. For example, you have until June 30 at 11:59 PM to make your forecasts for July. Same goes for August and September. There are Amazon gift card prizes for the top 3 finishers at values of $400, $300, and $200, courtesy of the Arizona Institutes for Resilient Environments and Societies. Mike, Zack, and Ben will be talking about the monsoon and the leaderboard each month on the Southwest Climate Podcast. For more details or to play: https://monsoonfantasy.arizona.edu/home Calling last year's monsoon fantasy players - Can you spare 2 minutes to help? If you played last year, the game team would be grateful for two minutes of your time to answer five simple questions. Responses are anonymous. They will help them publish a description of the game.  https://uarizona.co1.qualtrics.com/jfe/form/SV_bd88HC6pAoWjGwS  

Dear scribblers + speakers, June is PTSD Awareness Month. Trauma is not the event, it's the aftershocks of the event. Overthinking + overcontrolling could be post-traumatic responses/strategies that have been part of your survival. The embodied question is: As you work-play through the narrative of your trauma (and its legacy), what rituals will have helped you seek transformative intervention? (don't overthink this, we all have rituals—we simply don't name them as such.) Embodiment CTA (Call to Abide): Take the Rest Assessment - Go from routine to ritual as you Notice + Nurture + Embody your cyclical rhythms. You'll receive your ritual-specific, personalized recommendation, which will help you tune into your body's wisdom to optimize tending to your rhythmic soul care. Therapy: Therapy for Black Girls Explore Trauma Therapy: Consider EDMR, CBT, and somatic approaches as you assimilate the broken-up bits of sensory memories. Ase' + Amen Mohawkmomma Soul Podcast is brought to you by Mohawkmomma Soul Care Boutique, created + curated by Andrea "Angie" Palmer. You can also Subscribe by RSS. Journaling Prompt: Notepad PDF (free download) Meditative Playlists: TranquiliTEA Braid Grief with Grace Connect + Discover More: Email: andrea@mohawkmommastudio.com Youtube: Mohawkmomma Studio IG: @mohawkmommasoulcare How to support my work? 1. SIGNUP for Mohawkmomma Studio Forum—a soul care social media platform. 2. Join my Patreon Parishioners to support the podcast (and beyond) monthly. Wanna go deeper? Register for the FREE Soul Care Narrative Online Course created by Andrea "Angie" Palmer. 3. Give one time (or more) to my pastoral mission via PayPal or Cash app - $AndreaBeloved 4. Shop stunning soul care stationery. --- Send in a voice message: https://anchor.fm/mohawkmomma/message Support this podcast: https://anchor.fm/mohawkmomma/support

In this episode, I'm joined by Abigail Turner. Abigail is a mother, registered nurse, and embodiment guide. And this is one conversation that not only flows naturally and covers a wide range of topics, but manages to go deep with many of them as well. If you enjoy being exposed to new ideas and ways of thinking about emotions, parenting, spirituality, and more, then this is one episode you're not going to want to miss.Inside The Episode:Abigails preferred red pill to share with the masses Bradley's number one red pill to wake people up withHow properly deal with pent-up or recurring emotions Why she went to live in the forest with her 2-year-old and how it changed her lifeWhy most people overestimate the permanence of decisionsHow to make sense out of abstract, metaphysical conceptsTips for solo moms to maintain their identities as individualsWhy it truly takes a village to raise childrenHow to parent effectively without relying on punishmentsWant More Not Most People? - Ways To Get Involved/Stay ConnectedJoin The Not Most People AllianceFollow Not Most People On InstagramSubscribe & Turn On New Episode Notifications Connect With AbigailFollow Abigail On InstagramWant To Show Your Support?Leave A Review  On iTunesLeave A Review On AudibleConnect With BradleyBradley's InstagramSupport the show

Shelly and Cam continue on the theme of habitual responses by looking at expectations. An expectation is basically a belief that something will happen at some future date. You can appreciate how expectations may be problematic for those of us with ADHD - the delivery of something at some future point in time. Time estimation and struggles with activation go hand in hand here. So it makes sense we can develop some not-so-helpful responses to expectation. Cam shares three examples - ‘running the flag up the flagpole', where we elevate our own expectations and ‘do whatever it takes'; ‘bristle and defy' where we reject any expectation outright; and an emotional shame response where we go to our one-down position.  There are more responses, and Shelly and Cam invite listeners to think about their own responses to expectation. Shelly, fresh from a Phish tour weekend, adds the colorful examples for each scenario from setting up the campsite to challenges approaching our Discord server. Through discussion, the hosts reveal a useful process of getting awareness and perspective on the expectation, identifying our own relationship and response to the expectation, stepping back and releasing any attachment to the expectation, and then using the experience as a point of discussion to clarify and reflect on the experience to build a better relationship going forward. Episode links + resources: Join the Community | Become a Patron Our Process: Understand, Own, Translate. About Cam and Shelly For more of the Translating ADHD podcast: Episode Transcripts: visit TranslatingADHD.com and click on the episode Follow us on Twitter: @TranslatingADHD Visit the Website: TranslatingADHD.com

Some listeners ask whether it's ok to be one and done by choice, simply because they want to be? The answer, of course, is yes. Other folks talk about what happens when your birth control fails and considering terminating a pregnancy.  Someone schools Jess about Sex and the City, and then Jess talks about Gilmore Girls for 5-10 minutes. It is what it is. Enjoy! Email us at onlyyoupod@gmail.com to tell your story or ask questions of the community, and find us on Instagram or Facebook to be a part of the conversation. You can now support us on Patreon! We recently shifted that space to create a community of parents who can meet up and participate in events. All patrons at the $5 level or above can join us for two monthly mental health support groups via Zoom. Another great way to support us is to support the crowdfunding campaign for Jess's new book series all about an only child, Ruby June! Also remember to please leave us a review wherever you get your podcasts.

KUNR Youth Media student reporters crafted questions for Washoe County School Board candidates. KUNR's Lucia Starbuck and Nick Stewart break down what local high school students are concerned about this election and what the candidates had to say.

CW Today with Loretta Walker is heard each weekday at 12:05 Central Time on Faith Music Radio. Learn more about Loretta, her family and their ministries at ChristianWomanhood.org. Follow Loretta on Facebook - https://www.facebook.com/ChristianWomanhood

Are you ready for Shofar-Blowing, Jesus praising, Power-Packed Wednesday Morning session with Stacy Whited?! If not, then get your mind right because we are LIVE at 11:11AM CST.Videos and Resources Referenced in the Show - 11th Hour22:11-23:3028:35-38:3148:37-50:17https://youtu.be/oQ5svL23L8E Dutch Sheets June 8th0-11:24https://youtu.be/H4RwIixxctQ Hank Kunneman35:21-42:33https://youtu.be/wVDBWQjT3no Julie Green June 2 delivered Friday June 3rd5:57-16:39https://rumble.com/v176t4a-your-enemies-are-not-invincible.html June 7, 2022RED LINES “The Military have RED LINES that are set up as BOUNDARIES to protect your SECURITY and FREEDOM. When these RED LINES are crossed by an enemy (from without or within), they have RESPONSES that they ACTIVATE. You will, in fact, see this played out in your Nation, as darkened hearts desperately launch schemes to gain complete POWER and CONTROL, and your Military is forced to INTERVENE to stop these wicked schemes. I also have RED LINES in the Heavenly realms to protect My Kingdom on earth and the people who bear My name. Daily, these darkened spiritual forces and those on earth partnered with them, are CROSSING My RED LINES. Their IDOLATRY, their MURDER of innocent lives, their gross PERVERSION have all crossed My RED LINES. Because My Army of Light is calling for My JUDGMENT and JUSTICE, I will ARISE and I will come to your RESCUE. Heaven is MOUNTING A MASSIVE INVASION like earth has never before seen, and I will MOW DOWN your enemies until they are DUST beneath your feet. The WEALTH of the wicked will be used to RESTORE My people and the nations who acknowledge Me as Lord. The RED LINES are crossed; now get ready for HEAVEN'S INVASION!” Diana LarkinA Watchman's Journal  VideoPastor Robin (wife) 6:46-8:44https://youtu.be/oQ5svL23L8E  Psalm 35Psalm 91TO WATCH ALL OF THE PROPHETIC REPORTS -https://banned.video/playlist/61e604428362a67d2b03e4b7SPONSORS FOR TODAY'S VIDEO►  ReAwaken America- text the word EVENTS to 40509(Message and data rates may apply. Terms/privacy: 40509-info.com)►  Kirk Elliott PHD - http://FlyoverGold.com ►  My Pillow - https://MyPillow.com/Flyover►Z-Stack - https://flyoverhealth.com -------------------------------------------Be Blessed!- The Flyover TeamBusiness or Media, please contact us at:info@flyoverconservatives.comSupport the show

Tony shares his life story on this episode and we discuss his childhood, joining the military in Australia at age 16, serving in war zones, his addiction to alcohol and overcoming that, what his time in the military has taught him about leadership and teams and founding Halo Training which takes people into nature and gives them real life leadership opportunities based on the instructors' military backgrounds.  If you enjoy this conversation there are 308 others on seeds so check them out and more info at www.theseeds.nz  Halo Training: https://www.halotraining.co.nz  "Our experience was forged on the battlefields of Iraq, Afghanistan and other conflicts. We have led people through the most adverse and uncertain environments that could be asked of any team, or any leader, war.  Our military and intelligence backgrounds give us the unique ability to apply real-life technical and situational responses to corporate and business environments. Responses that deal with real pressure and real consequences. We focus on the human side of leadership, empowering people, teams and organisations to thrive in times of adversity."  

Steve Gruber discusses news and headlines.

Got some interesting responses about today's d-bags.

In episode 150 (!), I share some listener responses to last week's episode of the supportive variety. I'd love to hear from you, gimme an email at justinlmft@gmail.com. SNB 149 - https://www.justinlmft.com/post/episode149 Building Safety Anchors -https://www.justinlmft.com/bsa  Polyvagal 101 Class  - https://www.justinlmft.com/PVT101   Intro/Outro music & Transition Sounds by Benjo Beats - https://soundcloud.com/benjobeats   National Suicide Prevention Hotline - 1 (800) 273-8255 National Domestic Violence Hotline -1 (800) 799-7233 LGBT Trevor Project Lifeline - 1 (866) 488-7386 National Sexual Assault Hotline - 1 (800) 656-4673 Crisis Text Line - Text “HOME” to 741741 Call 911 for emergency   This and other content produced by Justin Sunseri (“JustinLMFT”) (i.e; podcast, YouTube, Instagram, etc.) is not therapy, not intended to be therapy or be a replacement for therapy.  Nothing in this creates or indicates a therapeutic relationship.  Please consult with your therapist or seek for one in your area if you are experiencing mental health sx.  Nothing should be construed to be specific life advice; it is for educational and entertainment purposes only.

Last week Cam and Shelly talked about habitual emotional responses to the stories we tell ourselves. This week they explore habitual responses in the context of time. Those of us with ADHD can have a complicated relationship with time. We can be extremely reactive to it, and we can be highly avoidant of it. Today the hosts share client examples of some classic habitual responses to time. Shelly and Cam reference the Eisenhower Decision Matrix tool that distinguishes importance and urgency in a task, especially Quadrant I items that are important and urgent and the ever-challenging Quadrant II items that are important and not urgent. With ADHD just ‘scheduling' our important items in the future is not enough. We have to first address the propensity to be drawn to the biggest signals - lit up by urgency and our level of interest. Shelly leads off with her own client example where her client struggled with scheduling the all-important case notes in her role as a special education teacher. As Shelly and her client start to look for the “big chunks” of time the client starts to shift her perspective, not only seeing the time but how the time would be valuable to address much more relevant tasks. In doing so, Shelly's client noticed and shifted away from her habit of thinking she needed big chunks to finish her notes. Cam follows with an example where the client's habitual response is to avoid undefined but less urgent tasks, pushing them to the next day on his calendar. These self-described “black boxes” were a source of underlying anxiety for Cam's client. But when the client let go of not knowing and embracing a narrow role of just assessing and defining the task, he could overcome his avoidant behavior. In both examples, the clients got curious and present to the opportunity at hand. Cam and Shelly leave listeners with some simple practices to start identifying and shifting habitual responses to time. Episode links + resources: Join the Community | Become a Patron Our Process: Understand, Own, Translate. About Cam and Shelly For more of the Translating ADHD podcast: Episode Transcripts: visit TranslatingADHD.com and click on the episode Follow us on Twitter: @TranslatingADHD Visit the Website: TranslatingADHD.com

This message is from the Witnesses sermon series, an expository series from the book of Acts.

Have you considered the legacy you will leave to those whose lives you touch? Does leaving a legacy need to be financial or something more?  This month we explore how to leave a lasting legacy in an organized way. You'll learn the ways that you can leave an enduring legacy during your life and beyond.  Today we are defining legacy and noodling on what that means both financially and non financially. Next week, we'll discuss the different strategies that you can use to leave a financial legacy, the following week we'll explore non-financial legacies, and in the 4th episode of this series, you'll learn how to create your own legacy strategy.  Live a life true to yourself Some people are spurred into retirement because they have trouble compartmentalizing work and so it bleeds into other areas of their lives. They choose retirement to escape the pace of a grueling work life. However, many high performers experience a lot of guilt upon retirement. They may feel an obligation to their team or their clients to continue working and feel held back by other people's expectations, but living a life true to yourself means letting go of others' expectations.  Learn how to not just survive retirement, but gain the confidence to rock retirement. Sign up for the 6-Shot Saturday newsletter to receive a weekly email with a summary of the answers to the questions from the show, plus links, tools, books, and other resources that will help you on your retirement journey What do you think of when you hear the word legacy?  When you hear the word legacy do you simply think of money or does legacy mean something more?  My mom died young–she was only 48 when she passed. When I think back on her legacy I don't consider the check I received from the lawyer a few months later. Instead, I am reminded of our conversations and debates on how best to live life. You could say that this podcast is an indirect result of her legacy.  Mom insisted on living a life of delayed gratification so that she could save for the future–a future that she never got to enjoy. I argued that living life in the present was the way to go. However, finding a balance between living well today and delaying gratification is the best way to live a life without regret. Ultimately, that is what this podcast is all aobut.  What does legacy mean?  The dictionary defines legacy as money or property given in a will, or something handed down from an ancestor.  When you die you will leave a legacy. What you choose to leave behind is up to you.  A nonfinancial legacy includes lessons, memories, and experiences that you share with others. How are you actively working to build a nonfinancial legacy in retirement?  A financial legacy could be money, property, or other mementos that generally come to your loved ones in a sterile way. A financial legacy could give your heirs the financial fuel they need to get started or continue on their journey through life. Make sure to tune in next week to hear what tools you can use to build your financial legacy.  OUTLINE OF THIS EPISODE OF THE RETIREMENT ANSWER MAN PRACTICAL PLANNING SEGMENT [5:35] What do you think of when you hear the word legacy? LISTENER QUESTIONS [14:48] A Daily Stoic blog post [16:14] Responses to Wendy's question about postponing travel [19:03] A Roth conversion question from Joel [22:22] Joe's question on planning for inflation [27:12] What should Joe's CFP be doing in response to the current market conditions? [33:02] Where I learned to fly fish in Colorado TODAY'S SMART SPRINT SEGMENT [34:17] Expand your thinking on legacy Resources Mentioned In This Episode Legacy Is Not for You from the Daily Stoic blog Boomer Benefits - check out their FREE 6-day mini-course! Episode 429 - Should I Retire Earlier If I Have Health Issues? IRS Publication 505 Rock Retirement Club Roger's YouTube Channel - Roger That BOOK - Rock Retirement  by Roger Whitney Roger's Retirement Learning Center